JP2010501607A5 - - Google Patents

Download PDF

Info

Publication number
JP2010501607A5
JP2010501607A5 JP2009525973A JP2009525973A JP2010501607A5 JP 2010501607 A5 JP2010501607 A5 JP 2010501607A5 JP 2009525973 A JP2009525973 A JP 2009525973A JP 2009525973 A JP2009525973 A JP 2009525973A JP 2010501607 A5 JP2010501607 A5 JP 2010501607A5
Authority
JP
Japan
Prior art keywords
calcium channel
channel blocker
hours
formulation
layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2009525973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010501607A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2007/007545 external-priority patent/WO2008025532A1/en
Publication of JP2010501607A publication Critical patent/JP2010501607A/ja
Publication of JP2010501607A5 publication Critical patent/JP2010501607A5/ja
Abandoned legal-status Critical Current

Links

JP2009525973A 2006-08-30 2007-08-29 ニソルジピンを含有する徐放性の固体状経口投与用配合剤 Abandoned JP2010501607A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82405406P 2006-08-30 2006-08-30
US82404306P 2006-08-30 2006-08-30
PCT/EP2007/007545 WO2008025532A1 (en) 2006-08-30 2007-08-29 Controlled release solid oral dosage formulations comprising nisoldipine

Publications (2)

Publication Number Publication Date
JP2010501607A JP2010501607A (ja) 2010-01-21
JP2010501607A5 true JP2010501607A5 (enExample) 2010-10-07

Family

ID=38686769

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009525973A Abandoned JP2010501607A (ja) 2006-08-30 2007-08-29 ニソルジピンを含有する徐放性の固体状経口投与用配合剤
JP2009525976A Pending JP2010501609A (ja) 2006-08-30 2007-08-29 コア層と１又は複数のバリヤー層を含む徐放性経口投与用配合剤
JP2014031474A Active JP5788547B2 (ja) 2006-08-30 2014-02-21 コア層と１又は複数のバリヤー層を含む徐放性経口投与用配合剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009525976A Pending JP2010501609A (ja) 2006-08-30 2007-08-29 コア層と１又は複数のバリヤー層を含む徐放性経口投与用配合剤
JP2014031474A Active JP5788547B2 (ja) 2006-08-30 2014-02-21 コア層と１又は複数のバリヤー層を含む徐放性経口投与用配合剤

Country Status (10)

Country Link
US (3) US20080057123A1 (enExample)
EP (2) EP2063871A1 (enExample)
JP (3) JP2010501607A (enExample)
KR (2) KR101575679B1 (enExample)
AU (2) AU2007291509B2 (enExample)
CA (2) CA2662122A1 (enExample)
ES (1) ES2547226T5 (enExample)
MX (2) MX2009002235A (enExample)
WO (2) WO2008025532A1 (enExample)
ZA (1) ZA200901688B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
MX2009001248A (es) 2006-08-03 2009-02-11 Nitec Pharma Ag Tratamiento con glucocorticoide de liberacion prolongada de enfermedad reumatoide.
ES2547226T5 (es) * 2006-08-30 2020-06-12 Jagotec Ag Formulaciones de dosificación oral de liberación controlada que comprenden un núcleo y una o más capas de barrera
EP2180883B1 (en) * 2007-07-23 2017-01-11 Pharmathen S.A. Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof
EP2187873B1 (en) 2007-08-13 2018-07-25 Abuse Deterrent Pharmaceutical Llc Abuse resistant drugs, method of use and method of making
AU2009224254A1 (en) * 2008-03-11 2009-09-17 Takeda Pharmaceutical Company Limited Orally-disintegrating solid preparation
MX2011001384A (es) 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
EP2331094A4 (en) * 2008-08-29 2011-10-26 Uab Research Foundation NOVEL AGENT AGAINST ARTHHYTHMIA
KR20100069170A (ko) * 2008-12-16 2010-06-24 삼일제약주식회사 라시디핀 함유 과립 및 이를 포함하는 약학 조성물
TWI494108B (zh) * 2009-01-26 2015-08-01 Nitec Pharma Ag 糖皮質激素用以製備嚴重夜間氣喘用之於延遲釋放型的藥物之用途
US20100247646A1 (en) * 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Extended release tablets of nisoldipine
US20100260842A1 (en) * 2009-04-06 2010-10-14 Rashmi Nair Pseudoephedrine pharmaceutical formulations
US20100285125A1 (en) * 2009-05-07 2010-11-11 Padma Venkitachalam Devarajan Delivery system for poorly soluble drugs
JP5937004B2 (ja) 2009-05-18 2016-06-22 ドーズ メディカル コーポレーションＤｏｓｅ Ｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ 薬剤溶出眼内インプラント
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
WO2012071476A2 (en) 2010-11-24 2012-05-31 David Haffner Drug eluting ocular implant
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
EP3311667A1 (en) 2009-07-08 2018-04-25 Charleston Laboratories, Inc. Pharmaceutical compositions
CN106389381A (zh) 2009-12-02 2017-02-15 阿达玛斯医药公司 金刚烷胺组合物及其使用方法
US20110217373A1 (en) * 2010-01-29 2011-09-08 Kumaravel Vivek Extended release pharmaceutical compositions of guanfacine hydrochloride
EP2561892B1 (en) * 2010-03-31 2015-05-06 Mochida Pharmaceutical Co., Ltd. Easily dosable solid preparation
US20130252956A1 (en) * 2010-11-22 2013-09-26 Howard Kallender Methods of treating cancer
KR101572336B1 (ko) 2010-12-22 2015-11-26 퍼듀 퍼머 엘피 케이싱된 탬퍼 저항성 제어 방출 투여 형태
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
WO2013046453A1 (ja) 2011-09-30 2013-04-04 持田製薬株式会社 易服用性固形製剤
EP2919903B1 (en) 2012-11-14 2020-07-22 W.R. Grace & CO. - CONN. Compositions containing a biologically active material and a non-ordered inorganic oxide
WO2014123899A1 (en) 2013-02-05 2014-08-14 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10420726B2 (en) 2013-03-15 2019-09-24 Inspirion Delivery Sciences, Llc Abuse deterrent compositions and methods of use
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
KR102170642B1 (ko) * 2013-11-14 2020-10-27 코웨이 주식회사 기능성 제재 공급기 및 이를 포함하는 연수기
EP3148491B1 (en) 2014-05-29 2020-07-01 Glaukos Corporation Implants with controlled drug delivery features and manufacturing method for said implants
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
CA3012698A1 (en) * 2016-02-05 2017-08-10 Entrega Inc. Oral dosage form with drying agent for delivery of active agent
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
JP7003110B2 (ja) 2016-04-20 2022-01-20 ドーズ メディカル コーポレーション 生体吸収性眼球薬物送達デバイス
US10588974B2 (en) 2016-04-22 2020-03-17 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
US20200121652A1 (en) * 2017-06-16 2020-04-23 The Doshisha Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent
EP3639854A4 (en) 2017-06-16 2021-03-03 The Doshisha MTOR INHIBITIVE MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF OPHTHALMIC SYMPTOMS, DISORDERS, OR DISEASES AND USE THEREOF
AU2018320946B2 (en) 2017-08-24 2024-05-02 Adamas Pharma, Llc Amantadine compositions, preparations thereof, and methods of use
US10940116B2 (en) * 2017-10-25 2021-03-09 Chiesi Farmaceutici S.P.A. Delayed release deferiprone tablets and methods of using the same
US12303487B2 (en) 2018-11-19 2025-05-20 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
IT201800011120A1 (it) * 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide per la somministrazione di mesalazina o suoi derivati
US20220331257A1 (en) * 2019-03-01 2022-10-20 Avadel Legacy Pharmaceuticals, Llc Liquid pharmaceutical compositions with stable drug release profiles
CN114630656B (zh) * 2019-08-26 2025-03-21 埃斯普投资有限公司 黏膜黏附剂组合物及其使用方法
JP2024541083A (ja) * 2021-11-19 2024-11-06 ポール バーリア スシュマ フラボキサートの制御放出製剤及びその調製方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62120315A (ja) * 1985-11-20 1987-06-01 Shin Etsu Chem Co Ltd 経口投与型徐放性錠剤の製造方法
DE3636123A1 (de) * 1986-10-23 1988-05-05 Rentschler Arzneimittel Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten
US5015479A (en) * 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
DE3720757A1 (de) * 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
NO883326L (no) * 1987-08-11 1989-02-13 Bayer Ag Dhp-retard-tilberedning.
DE3814532A1 (de) * 1988-04-29 1989-11-09 Bayer Ag Dhp-retard-zubereitung
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
IT1251153B (it) * 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
US6235313B1 (en) * 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
IT1265240B1 (it) * 1993-11-30 1996-10-31 Ekita Investments Nv Compressa farmaceutica a rilascio controllato, di forma lenticolare
GB9402203D0 (en) 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
US6103263A (en) * 1994-11-17 2000-08-15 Andrx Pharmaceuticals, Inc. Delayed pulse release hydrogel matrix tablet
JP2849047B2 (ja) * 1994-12-19 1999-01-20 大正薬品工業株式会社 ジクロフェナクナトリウム持続性製剤およびその製法
US5534263A (en) * 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US6083532A (en) * 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5900425A (en) * 1995-05-02 1999-05-04 Bayer Aktiengesellschaft Pharmaceutical preparations having controlled release of active compound and processes for their preparation
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
IT1282576B1 (it) * 1996-02-06 1998-03-31 Jagotec Ag Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili
IT1282650B1 (it) 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
US5955096A (en) * 1996-06-25 1999-09-21 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
IT1289160B1 (it) * 1997-01-08 1998-09-29 Jagotec Ag Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di
US5922352A (en) * 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
IT1294760B1 (it) * 1997-09-03 1999-04-12 Jagotec Ag Procedimento per la preparazione di compresse farmaceutiche in grado di cedere,secondo schemi predeterminabili, principi attivi poco
NZ513037A (en) * 1999-01-29 2003-05-30 Disphar Internat B Coated sustained release pharmaceutical composition for the release of an agent in the gastrointestinal tract
DE19906290A1 (de) * 1999-02-15 2000-08-17 Falk Pharma Gmbh Arzneimittel zur Behandlung bzw. Prävention von Darmkrebs
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
DE10115216A1 (de) * 2001-03-28 2002-10-10 Bosch Gmbh Robert Kraftstoffeinspritzventil für Brennkraftmaschinen
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
EP2359817B1 (en) * 2003-03-28 2018-01-10 Sigmoid Pharma Limited Solid oral dosage form containing seamless microcapsules
JP2005132803A (ja) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd 胃内滞留固形剤
WO2005070463A2 (en) 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprising (s)-amlodipine malate and an angiotensin receptor blocker and methods of their use
DE602005010899D1 (de) 2004-09-27 2008-12-18 Sigmoid Pharma Ltd Mikrokapseln mit einem methylxanthin und einem kortikosteroid
ES2547226T5 (es) * 2006-08-30 2020-06-12 Jagotec Ag Formulaciones de dosificación oral de liberación controlada que comprenden un núcleo y una o más capas de barrera

Similar Documents

Publication Publication Date Title
JP2010501607A5 (enExample)
JP5658172B2 (ja) アムロジピン及びロサルタンを含む固形薬剤学的組成物及びその製造方法
AU2006241771B2 (en) Composition containing anti-dementia drug
CA2842452C (en) Sustained-release preparation of ivabradine or pharmaceutically acceptable salts thereof
HU222252B1 (hu) Eljárás dihidropiridin-típusú Ca-antagonistát tartalmazó nyújtott hatóanyag-leadású gyógyszerkészítmények előállítására
JP2010501607A (ja) ニソルジピンを含有する徐放性の固体状経口投与用配合剤
ITMI972003A1 (it) Procedimento per la preparazione di compresse farmaceutiche in grado di cedere,secondo schemi predeterminabili, principi attivi poco
TW201018461A (en) Pharmaceutical compositions containing diacerein
WO2004064815A1 (en) Oral dosage formulation
JP5948648B2 (ja) 安定化されたエペリゾンを含有する徐放性製剤
CA2642851A1 (en) Low flush niacin formulation
WO2011069076A2 (en) Sustained release donepezil formulations
FI88872B (fi) Foerfarande foer framstaellning av sferoider, som aostadkommer laongvarig foerdroejd frigoering av en som kalciumkanalblockerare anvaend dihydropyridin
CN102917696A (zh) 在每日施用一次时提供最佳药理学临床效应的醋氯芬酸缓释制剂
JP5854371B2 (ja) カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤
AU2009256394A1 (en) Modified release niacin formulations
JP4439499B2 (ja) アムロジピン含有粒子およびそれからなる口腔内崩壊錠
CN1333683A (zh) 改进释放的胰岛素致敏物的药用组合物
US20060246003A1 (en) Composition containing anti-dementia drug
WO2013013351A1 (zh) 复方甲氧那明的速释-缓释渗透泵制剂
US9480681B2 (en) Controlled release formulations of nisoldipine
CN101874802A (zh) 一种治疗高血压和高胆固醇的缓释药物组合物
TW520298B (en) Oral morphine multiparticulate formulation
TW200803830A (en) Methods and formulations for making controlled release oral dosage form
JP2006504686A (ja) プラバスタチンの医薬品製剤およびそれらの使用方法